Dermatology

Original New Drug Application Approvals by US FDA (16-31 December 2023)

03 Jan 2024

New drug applications approved by US FDA as of 16-31 December 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Acitretin plus triamcinolone treats oral lichen planus better than triamcinolone monotherapy

21 Dec 2023

The combination of oral acitretin plus topical triamcinolone acetonide (TAC) appears to have superior efficacy than TAC alone in the treatment of patients with oral lichen planus, as shown in a study.

Long-term risankizumab safe, effective in moderate-to-severe plaque psoriasis

Stephen Padilla, 20 Dec 2023

Treatment with risankizumab in the long term shows lasting efficacy against moderate-to-severe plaque psoriasis and has good tolerability, according to the LIMMitless study.

Original New Drug Application Approvals by US FDA (01-15 December 2023)

18 Dec 2023

New drug applications approved by US FDA as of 01-15 December 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Low-dose methotrexate may pose serious adverse event risk for older adults with CKD

Jairia Dela Cruz, 05 Dec 2023

For older adults with chronic kidney disease (CKD) who are initiating a disease-modifying antirheumatic drug (DMARD), low-dose methotrexate appears to be associated with a heightened 90-day risk of serious adverse events compared with hydroxychloroquine, as shown in a study.

Givosiran delivers safe, sustained improvements in acute hepatic porphyria

Stephen Padilla, 28 Nov 2023

Long-term monthly treatment with givosiran has good tolerability and offers continuous improvements to patients with acute hepatic porphyria (AHP), results of the phase III ENVISION trial have shown.

Roflumilast improves skin clearance in patients with AD

Elaine Soliven, 27 Nov 2023

Once-daily treatment with topical roflumilast cream 0.15% demonstrates a significant improvement in vIGA-AD* score, achieving a clear or almost clear status, in patients with mild-to-moderate atopic dermatitis (AD), according to the pooled analysis of the phase III INTEGUMENT-1/2 studies presented at ACAAI 2023.

WCD 2023: Updates on abrocitinib’s efficacy in moderate-to-severe atopic dermatitis

Dr. Claire Clibborn, Dr. Erman Güler, Prof. Andrew Alexis, 18 Oct 2023

Janus kinase (JAK) inhibition has emerged as a novel approach in systemic treatment of moderate-to-severe atopic dermatitis (AD). This article summarizes results of select phase III studies of the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development programme investigating the safety and efficacy of abrocitinib, a selective JAK1 inhibitor, in patients with moderate-to-severe AD, which were presented at the 25th World Congress of Dermatology (WCD) held in Singapore.

Protecting adults against herpes zoster: Why it matters

25 Mar 2023

Herpes zoster occurs when the varicella zoster virus that lay dormant in the body after recovering from chickenpox reactivate later in life. Complications from herpes zoster can cause chronic, debilitating pain and disability. Three clinicians share why preventing herpes zoster matters for everyone.

Anti–IL-23 management of severe psoriatic arthritis in a heavily pretreated young obese patient

Dr. Billy Lai, 20 Feb 2023

The patient is a 29-year-old male who was first diagnosed with psoriatic arthritis (PsA) in November 2010. He had comorbid well-controlled epilepsy and obesity, with body weight fluctuating between 100 kg and 107 kg in recent years.

Remibrutinib improves CSU symptoms in phase III trials

Elvira Manzano, 05 Dec 2023

Treatment with the investigational, oral Bruton’s tyrosine kinase (BTK) inhibitor remibrutinib improves symptoms in patients with chronic spontaneous urticaria (CSU) inadequately controlled on antihistamines, the phase III REMIX-1 and -2 studies have shown.

Roflumilast improves skin clearance in patients with AD

Elaine Soliven, 27 Nov 2023

Garadacimab provides early protection against HAE attacks

Elaine Soliven, 24 Nov 2023

Subcutaneous prophylactic treatment with garadacimab significantly reduced the monthly number of attacks and led to attack-free status as early as week 1 in patients with hereditary angioedema (HAE) in the post hoc analysis of the phase III VANGUARD study presented at ACAAI 2023.

Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients

Stephen Padilla, 17 Nov 2023

Treatment with dupilumab increases the levels of bone alkaline phosphatase (BALP), a marker of bone mineralization, in paediatric patients with moderate-to-severe atopic dermatitis (AD), regardless of asthma comorbidity, reports a study presented at ACAAI 2023.

Brentuximab vedotin fares well for CTCL in real-world study

Audrey Abella, 26 Oct 2023

Interim findings from a prospective real-world study in Poland demonstrated favourable clinical outcomes and a tolerable safety profile for the CD30-directed antibody-drug conjugate brentuximab vedotin in patients with CD30-expressing cutaneous T-cell lymphoma (CTCL).

How safe is long-term bimekizumab in plaque psoriasis patients?

Stephen Padilla, 24 Oct 2023

Treatment with bimekizumab (BKZ) for over 3 years does not result in the occurrence of new adverse events (AEs), demonstrating its positive safety profile in patients with moderate-to-severe plaque psoriasis, as shown by a pooled analysis of five phase III/IIIb trials presented at EADV 2023.

Risankizumab proven safe, effective in bio-naïve psoriasis patients

Stephen Padilla, 24 Oct 2023

Treatment with risankizumab (RZB) results in significantly lower absolute Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores at week 52 in bio-naïve psoriasis patients compared with other biologic therapies, according to the results of a 2-year interim analysis from the German cohort of the VALUE study, presented at EADV 2023.